Michael Ambrogi Biography and Net Worth

COO of NovoCure


Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide. From 1991 to 2006, Mr. Ambrogi worked for Deka Research and Development Corporation, inventor Dean Kamen’s research and development firm, last serving as general manager. Mr. Ambrogi led Deka’s teams on many products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent and the J&J IBOT 3000 mobility system. Earlier in his career, from 1988 to 1990, Mr. Ambrogi was a consultant with McKinsey & Company, a global management consultant firm. Mr. Ambrogi holds a S.B. in mechanical engineering from MIT.

What is Michael J. Ambrogi's net worth?

The estimated net worth of Michael J. Ambrogi is at least $3.73 million as of July 22nd, 2020. Mr. Ambrogi owns 221,167 shares of NovoCure stock worth more than $3,728,876 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Ambrogi may own. Learn More about Michael J. Ambrogi's net worth.

How do I contact Michael J. Ambrogi?

The corporate mailing address for Mr. Ambrogi and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Michael J. Ambrogi's contact information.

Has Michael J. Ambrogi been buying or selling shares of NovoCure?

Michael J. Ambrogi has not been actively trading shares of NovoCure during the last ninety days. Most recently, Michael J. Ambrogi sold 42,972 shares of the business's stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $67.02, for a transaction totalling $2,879,983.44. Following the completion of the sale, the chief operating officer now directly owns 221,167 shares of the company's stock, valued at $14,822,612.34. Learn More on Michael J. Ambrogi's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 11/1/2024.

Michael J. Ambrogi Insider Trading History at NovoCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2020Sell42,972$67.02$2,879,983.44221,167View SEC Filing Icon  
4/14/2020Sell27,519$71.00$1,953,849.00243,622View SEC Filing Icon  
2/25/2020Sell11,647$81.16$945,270.52216,873View SEC Filing Icon  
11/4/2019Sell80,819$79.00$6,384,701.00195,743View SEC Filing Icon  
6/19/2019Sell110,868$60.00$6,652,080.00296,542View SEC Filing Icon  
6/6/2019Sell5,999$54.79$328,685.21191,673View SEC Filing Icon  
6/4/2019Sell35,000$52.62$1,841,700.00203,174View SEC Filing Icon  
4/1/2019Sell34,375$47.39$1,629,031.25207,549View SEC Filing Icon  
2/28/2019Sell2,397$53.68$128,670.96171,702View SEC Filing Icon  
2/4/2019Sell58,500$49.21$2,878,785.00184,058View SEC Filing Icon  
2/1/2019Sell37,500$49.03$1,838,625.00184,058View SEC Filing Icon  
1/9/2019Sell100,000$40.00$4,000,000.00221,558View SEC Filing Icon  
7/2/2018Sell57,390$31.48$1,806,637.20174,383View SEC Filing Icon  
5/1/2018Sell60,000$27.40$1,644,000.00View SEC Filing Icon  
4/26/2018Sell20,000$26.01$520,200.00166,558View SEC Filing Icon  
4/18/2018Sell40,000$23.03$921,200.00166,558View SEC Filing Icon  
2/23/2018Sell8,458$19.83$167,722.14105,288View SEC Filing Icon  
11/3/2017Sell1,200$22.00$26,400.0024,987View SEC Filing Icon  
11/1/2017Sell24,327$22.01$535,437.2749,514View SEC Filing Icon  
12/22/2016Sell27,500$8.27$227,425.00139,084View SEC Filing Icon  
12/20/2016Sell20,000$8.62$172,400.00179,084View SEC Filing Icon  
12/19/2016Sell20,000$8.76$175,200.00179,084View SEC Filing Icon  
12/16/2016Sell40,000$8.93$357,200.00219,084View SEC Filing Icon  
12/14/2016Sell40,000$8.97$358,800.00259,084View SEC Filing Icon  
12/12/2016Sell15,000$9.01$135,150.00289,084View SEC Filing Icon  
12/8/2016Sell10,000$8.30$83,000.00299,084View SEC Filing Icon  
12/6/2016Sell10,000$8.24$82,400.00309,084View SEC Filing Icon  
6/8/2016Sell20,000$12.24$244,800.00324,084View SEC Filing Icon  
See Full Table

Michael J. Ambrogi Buying and Selling Activity at NovoCure

This chart shows Michael J Ambrogi's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $16.86
Low: $16.22
High: $17.35

50 Day Range

MA: $16.52
Low: $14.54
High: $18.57

2 Week Range

Now: $16.86
Low: $11.29
High: $24.74

Volume

673,942 shs

Average Volume

919,911 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71